Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease

Trial Profile

Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 01 Jun 2017 Planned End Date changed from 1 Jul 2021 to 30 Jun 2022.
    • 17 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top